Neo Ivy Capital Management’s DexCom DXCM Stock Holding History

Neo Ivy Capital Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-20,306	Closed	-$1.36M	–	307
2024 Q3	$1.36M	Sell	20,306 -5,354	-21%	-$440K	0.44%	98
2024 Q2	$2.91M	Buy	+25,660	New	+$3.24M	0.57%	82
2022 Q4	$291K	Buy	+2,568	New	+$282K	0.2%	195
2021 Q2	–	Sell	-484	Closed	-$43K	–	492
2021 Q1	$43K	Buy	+484	New	+$45.4K	0.05%	341
2020 Q4	–	Sell	-2,172	Closed	-$223K	–	460
2020 Q3	$223K	Buy	+2,172	New	+$227K	0.23%	176
2020 Q2	–	Sell	-332	Closed	-$22K	–	495
2020 Q1	$22K	Buy	+332	New	+$20.7K	0.04%	372
2019 Q4	–	Sell	-1,256	Closed	-$54K	–	294
2019 Q3	$54K	Buy	+1,256	New	+$48.8K	0.04%	245
2019 Q2	–	Sell	-18,560	Closed	-$552K	–	305
2019 Q1	$552K	Buy	+18,560	New	+$652K	0.31%	144

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Neo Ivy Capital Management's DXCM Position: Q4 2024 in Review

Neo Ivy Capital Management sold out of DexCom (DXCM) in Q4 2024, closing a stake of 20,306 shares — an estimated $1.36M sold.

Neo Ivy Capital Management first reported a position in DXCM in Q1 2019 and held it in 8 quarters. The position peaked at $2.91M in Q2 2024. 952 funds tracked by Wall St. Rank hold DXCM as of Q4 2024.

Neo Ivy Capital Management reported no remaining DexCom position as of Q4 2024 after selling out during the quarter.
Neo Ivy Capital Management sold 20,306 DexCom shares in Q4 2024, an estimated $1.36M.
Neo Ivy Capital Management first reported a position in DexCom in Q1 2019 and held it in 8 quarters.
Neo Ivy Capital Management's DexCom position peaked at $2.91M in Q2 2024.
952 funds tracked by Wall St. Rank held DexCom as of Q4 2024.

Based on Neo Ivy Capital Management's 13F filing for Q4 2024, filed 18 Feb 2025.